Novel therapeutic targets on the horizon for lung cancer.
about
Emerging therapeutic agents for lung cancerZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer.The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment.Gold nanoparticles enhance TRAIL sensitivity through Drp1-mediated apoptotic and autophagic mitochondrial fission in NSCLC cellsSrc-dependent EGFR transactivation regulates lung inflammation via downstream signaling involving ERK1/2, PI3Kδ/Akt and NFκB induction in a murine asthma model.PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients.Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers.Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.SNCA Is a Functionally Low-Expressed Gene in Lung Adenocarcinoma.On the "TRAIL" of a Killer: MMP12 in Lung Cancer.Potential Molecular Targets in the Treatment of Lung Cancer Using siRNA Technology.Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC).Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer.Exhaustive preoperative staging increases survival in resected adrenal oligometastatic non-small-cell lung cancer: a multicentre study.Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model.Acetyl-macrocalin B, an ent-kaurane diterpenoid, initiates apoptosis through the ROS-p38-caspase 9-dependent pathway and induces G2/M phase arrest via the Chk1/2-Cdc25C-Cdc2/cyclin B axis in non-small cell lung cancer.Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis.Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer.Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis.Elevated expression of podoplanin and its clinicopathological, prognostic, and therapeutic values in squamous non-small cell lung cancer.Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study.Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models.MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinomaCombination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer
P2860
Q28070165-A77F3B90-63F6-4D6C-AA02-03755BA8CB07Q33760046-B4A91DA8-BE32-40D5-A6B5-015E37F8A013Q37571181-68CC742B-01AC-496B-B4A2-7A3601174007Q37739975-AC53E33A-4F8B-4730-A437-FE9CA9F7A53FQ41565956-9684EE4F-B8BF-40B1-BE5B-82FBDCEA7213Q42354900-D34B94C0-58D3-4096-BFD2-2FC981E1BED6Q47100164-3EBD0C41-EFF8-4EC7-BCED-53C22B8771A9Q47166342-93E8C6F0-8865-4C88-B874-82A9AC159CF6Q47210545-41D45615-FF88-421C-887F-46BB999AC637Q48004932-1A90AF55-88B7-4E0B-A40E-A6084C7F0C75Q48536576-786864F4-6D63-497D-92E5-3B6330941ED0Q49188022-80A70A77-E8A4-4F9C-8B6C-1D2CC6109F5EQ49417517-6B023B6C-D2D1-4818-843B-52469B8C99EEQ50204641-1D7D10C2-1454-40CD-8613-D8D228C3130AQ52633438-8CF0F43F-0055-457A-9061-1826D7FC65C6Q52642804-F9884CDD-D2DD-4620-9C64-3DE547367B3AQ52653002-11CA4FBC-0CA0-4E8B-9A79-DD47D2B1E587Q52726981-E9C7C329-16C7-4FD5-AA88-4245ABDF2EC8Q54948216-2969B59C-6DCE-4AA8-8E19-B32D61EB6BC1Q54964718-0AC1ED9E-7F44-4BE0-84F3-F222D1332A29Q54978516-47AE7714-B12E-4225-B766-C42F7A4CE222Q55110585-B76180D5-E589-4471-B318-F75EC8453CB1Q58770545-A1C96FB5-B6AF-496E-BC12-D6CB9718E74CQ58770914-0F968D40-64C8-47B4-8E90-FE0658DE84C6
P2860
Novel therapeutic targets on the horizon for lung cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Novel therapeutic targets on the horizon for lung cancer.
@ast
Novel therapeutic targets on the horizon for lung cancer.
@en
type
label
Novel therapeutic targets on the horizon for lung cancer.
@ast
Novel therapeutic targets on the horizon for lung cancer.
@en
prefLabel
Novel therapeutic targets on the horizon for lung cancer.
@ast
Novel therapeutic targets on the horizon for lung cancer.
@en
P2093
P50
P1433
P1476
Novel therapeutic targets on the horizon for lung cancer
@en
P2093
Angela Takano
Axel M Hillmer
Daniel S W Tan
Eng-Huat Tan
N Gopalakrishna Iyer
Wan-Ling Tan
P304
P356
10.1016/S1470-2045(16)30123-1
P577
2016-08-01T00:00:00Z